Richard Moxley III, M.D. Retires
|
|
After a career of more than forty years, Richard Moxley plans to retire on July 1, 2017. He is one of the founders of the URMC Department of Neurology and is widely recognized for his work focusing on muscular dystrophy. He is a passionate advocate of patient-centered care, addressing the common disconnect between physicians and patients. He helped to develop tools that help physicians and researchers determine which symptoms have the greatest impact on the quality of patients’ lives and how to meaningfully measure the effectiveness of new treatments.
Moxley was director of the Clinical Research Center, a CTSI-affiliated resource for researchers conducting clinical research at URMC, and also co-directed the CTSI’s Pilot Studies Program.
Moxley intends to continue to stay active in myotonic dystrophy research by advising the National Institute of Arthritis and Musculoskeletal and Skin Diseases and the Myotonic Dystrophy Foundation. The Department of Neurology is planning a celebration of his career to be held in May 2018. Read more about Dr. Moxley’s distinguished career on the CTSI Stories Blog.
|
|
Reducing Delay in Diagnosis of Malignancy Through Radiology Recommendation Tracking
|
|
|
|
Presented by: Ben Wandtke, MD, MS,
Associate Professor, Department of Imaging Sciences
|
|
This special grand rounds seminar will present a new program that is meant to reduce delayed or missed diagnoses of malignancy by "closing the loop" on radiology recommendations such as for follow-up of incidental findings. This approach minimizes added work for ordering providers and increases the reliability of the follow-up process.
Panel:
Stephen Judge MD, Assistant Professor of Clinical Medicine & Medical Director, UR Medicine Primary Care Network
David Dougherty MD, Chief Quality & Safety Officer, Wilmot Cancer Center
Robert Panzer MD, Georgia & Thomas Gosnell Professor in Quality and Safety
To view the streaming videos that will be posted several days after the grand rounds, go to Hospital-Wide Patient Safety Grand Rounds.
Lunch will be served.
Date: Friday, June 16th
Time: 12:00 – 1:00 pm
Location: URMC - Class of ’62 Auditorium (1-9425)
|
|
Understanding the Heterogeneity and Dynamics of Responses to Immune Checkpoint Blockade for Melanoma
|
|
|
|
Presented by: Alexandre Reuben, PhD, MD Anderson Cancer Center, Houston, Texas, Faculty Candidate, Cancer Biology, Wilmot Cancer Institute Postdoctoral Fellow, Surgical Oncology
|
|
Dr. Reuben is a translational scientist who holds a Ph.D. in Tumor Immunology from the University of Montreal. His research focus is to understand the heterogeneity and dynamics of responses to checkpoint blockade immunotherapy in metastatic melanoma.
Date: Monday, June 12th
Time: 2:00 – 3:00 pm
Location: URMC – WCI Formicola Conference Room (2-0727)
|
|
Immune-Modulating Approaches to Cancer Therapy: Focusing on Combinations
|
|
|
|
Presented by: Jedd D. Wolchok, MD, PhD, Lloyd J. Old/Virginia and Daniel K. Ludwig Chair in Clinical Investigation; Chief, Melanoma & Immunotherapeutics Service; Director, Parker Institute for Cancer Immunotherapy at MSK; Associate Director, Ludwig Center for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center
|
|
|
Dr. Wolchok is a medical oncologist who specializes in caring for people with melanoma. As a researcher, he is working to develop innovative ways to use the immune system to treat cancer and has been at the forefront of cancer immunotherapy as a clinician-scientist and as a principal investigator of several pivotal clinical trials.
Date: Friday, June 16th
Time: 12:00 - 1:00 pm
Location: URMC - WCI Formicola Conference Room (2-0727)
|
|
ICMJE Announces New
Data Sharing Plan Requirements
|
|
|
The International Committee of Medical Journal Editors (ICMJE) has new requirements for clinical trials. In order to be considered for publication, manuscripts submitted after July 1, 2018 must include a data sharing statement in the manuscript’s submission. Data sharing statements must indicate the following: whether individual de-identified participant data (including data dictionaries) will be shared; what data in particular will be shared; whether additional, related documents will be available (e.g., study protocol, statistical analysis plan, etc.); when the data will become available and for how long; by what access criteria data will be shared (including with whom, for what types of analyses, and by what mechanism). Clinical trials that begin enrolling after January 1, 2019 must include a data sharing plan on ClinicalTrials.gov.
For more information about these new requirements contact researchhelp@urmc.rochester.edu
|
|
|
|
|
